Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (51-60 of 685) with videos related to

Pageof 69
Sort By:
Oncotarget|September 17, 2016
Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panelChan Shen, Funda Meric-Bernstam, Xiaoping Su, et al.
Growth Factors (Chur, Switzerland)|December 17, 2008
Regulation and localization of ribosomal protein S6 kinase 1 isoformsDoyil Kim, Argun Akcakanat, Gopal Singh, et al.
Oncotarget|December 21, 2019
Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cellsMing Zhao, Ming-Lei Zhuo, Xiaofeng Zheng, et al.
Bioinformatics (Oxford, England)|June 30, 2012
PurityEst: estimating purity of human tumor samples using next-generation sequencing dataXiaoping Su, Li Zhang, Jianping Zhang, et al.
Oncotarget|February 5, 2019
FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cellsMing Zhao, Ming-Lei Zhuo, Xiaofeng Zheng, et al.
Expert Opinion on Investigational Drugs|August 14, 2018
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapySiqing Fu, Yudong Wang, Khandan Keyomarsi, et al.
Cell Genomics|February 13, 2023
Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencingJake Leighton, Min Hu, Emi Sei, et al.
Human Pathology|August 4, 2025
Emerging molecular Therapeutic targets in breast Cancer: Pathologic identification and clinical implicationsAysegul A Sahin, Hui Chen, Huang Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Accelerated approval and breakthrough therapy designation: oncology drug development on speed?James C Yao, Funda Meric-Bernstam, J Jack Lee, et al.
Journal of the National Cancer Institute|November 9, 2017
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma TumorsShiraj Sen, Funda Meric-Bernstam, David S Hong, et al.
Pageof 69

Showing results (51-60 of 685) with videos related to

Sort By:
Pageof 69
Oncotarget|September 17, 2016
Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panelChan Shen, Funda Meric-Bernstam, Xiaoping Su, et al.
Growth Factors (Chur, Switzerland)|December 17, 2008
Regulation and localization of ribosomal protein S6 kinase 1 isoformsDoyil Kim, Argun Akcakanat, Gopal Singh, et al.
Oncotarget|December 21, 2019
Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cellsMing Zhao, Ming-Lei Zhuo, Xiaofeng Zheng, et al.
Bioinformatics (Oxford, England)|June 30, 2012
PurityEst: estimating purity of human tumor samples using next-generation sequencing dataXiaoping Su, Li Zhang, Jianping Zhang, et al.
Oncotarget|February 5, 2019
FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cellsMing Zhao, Ming-Lei Zhuo, Xiaofeng Zheng, et al.
Expert Opinion on Investigational Drugs|August 14, 2018
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapySiqing Fu, Yudong Wang, Khandan Keyomarsi, et al.
Cell Genomics|February 13, 2023
Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencingJake Leighton, Min Hu, Emi Sei, et al.
Human Pathology|August 4, 2025
Emerging molecular Therapeutic targets in breast Cancer: Pathologic identification and clinical implicationsAysegul A Sahin, Hui Chen, Huang Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Accelerated approval and breakthrough therapy designation: oncology drug development on speed?James C Yao, Funda Meric-Bernstam, J Jack Lee, et al.
Journal of the National Cancer Institute|November 9, 2017
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma TumorsShiraj Sen, Funda Meric-Bernstam, David S Hong, et al.
Pageof 69